MoonLake Immunotherapeuti... (MLTX)
42.15
0.25 (0.60%)
At close: Feb 20, 2025, 3:59 PM
42.10
-0.11%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 41 |
| Market Cap | 2.66B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.27 |
| PE Ratio (ttm) | -33.19 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 42.99 |
| Volume | 134,279 |
| Avg. Volume (20D) | 327,477 |
| Open | 41.93 |
| Previous Close | 41.90 |
| Day's Range | 41.11 - 42.37 |
| 52-Week Range | 37.55 - 58.26 |
| Beta | undefined |
About MLTX
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 20, 2020
Employees 50
Stock Exchange NASDAQ
Ticker Symbol MLTX
Website https://www.moonlaketx.com
Analyst Forecast
According to 7 analyst ratings, the average rating for MLTX stock is "Buy." The 12-month stock price forecast is $82, which is an increase of 94.57% from the latest price.
Buy 71.43%
Hold 14.29%
Sell 0.00%
1 month ago
+5.64%
MoonLake Immunotherapeutics shares are trading hig...
Unlock content with
Pro Subscription
11 months ago
+3.16%
MoonLake Immunotherapeutics shares are trading higher after the company announced improvements across all key outcomes from its 24-week data from the ARGO trial in psoriatic arthritis and other R&D updates.
